Statistical quantification of nonlinear interference noise components in coherent systems.

We present and validate a statistical method able to separate nonlinear interference noise (NLIN) into a residual Gaussian (ResN) and a phase noise (NLPN) component. We take into account the interaction of the NLIN with the receiver's DSP, mainly through carrier phase recovery (CPR), by considering the amount of correlation of the NLPN component. This allows obtaining in a straightforward way an accurate prediction of the achievable post-DSP transmission performance.

High-gain 1.3 μm GaInNAs semiconductor optical amplifier with enhanced temperature stability for all-optical signal processing at 10 Gb/s.

We report on the complete experimental evaluation of a GaInNAs/GaAs (dilute nitride) semiconductor optical amplifier that operates at 1.3 μm and exhibits 28 dB gain and a gain recovery time of 100 ps. Successful wavelength conversion operation is demonstrated using pseudorandom bit sequence 2-1 non-return-to-zero bit streams at 5 and 10  Gb/s, yielding error-free performance and showing feasibility for implementation in various signal processing functionalities.

Bandpass sampling in heterodyne receivers for coherent optical access networks.

A novel digital receiver architecture for coherent heterodyne-detected optical signals is presented. It demonstrates the application of bandpass sampling in an optical communications context, to overcome the high sampling rate requirement of conventional receivers (more than twice the signal bandwidth). The concept is targeted for WDM coherent optical access networks, where applying heterodyne detection constitutes a promising approach to reducing optical hardware complexity.

Quaternary TDM-PAM as upgrade path of access PON beyond 10Gb/s.

A 20 Gb/s quaternary TDM-PAM passive optical network with chirped and non-linear optical transmitters is experimentally demonstrated. The migration from legacy TDM-PONs and the implications of using available 10 Gb/s components are analyzed. We show that a loss budget of 27.

Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.

8 patients with advanced prostatic carcinoma were treated with the luteinising-hormone releasing-hormone agonist, ICI 118630, for up to 3 months. Patients received subcutaneous injections of ICI 118630 (either 100 micrograms or 250 micrograms daily). At the higher dose level, plasma testosterone concentrations were significantly reduced by day 14 and approximated to those previously recorded in castrated or diethylstilboestrol-treated patients.